Leerink Swann set a $100.00 target price on Express Scripts (NASDAQ:ESRX) in a research note published on Thursday morning, Marketbeat.com reports. The brokerage currently has a hold rating on the stock. Leerink Swann also issued estimates for Express Scripts’ Q4 2018 earnings at $2.68 EPS, FY2018 earnings at $9.10 EPS, Q1 2019 earnings at $1.82 EPS, Q2 2019 earnings at $2.28 EPS, Q3 2019 earnings at $2.51 EPS, Q4 2019 earnings at $2.90 EPS and FY2020 earnings at $8.15 EPS.
A number of other equities analysts have also weighed in on the company. BidaskClub raised Express Scripts from a hold rating to a buy rating in a research note on Tuesday, September 18th. Credit Suisse Group lowered Express Scripts from an outperform rating to a neutral rating and upped their price objective for the stock from $90.00 to $96.50 in a research note on Tuesday, September 18th. ValuEngine raised Express Scripts from a hold rating to a buy rating in a research note on Monday, September 17th. Royal Bank of Canada upped their price objective on Express Scripts to $94.00 and gave the stock an outperform rating in a research note on Monday, August 27th. Finally, Robert W. Baird lowered Express Scripts from an outperform rating to a neutral rating and set a $81.00 price objective for the company. in a research note on Friday, July 20th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Express Scripts presently has an average rating of Hold and a consensus target price of $88.79.
Shares of NASDAQ ESRX traded down $0.50 during mid-day trading on Thursday, reaching $96.74. The company’s stock had a trading volume of 1,900,585 shares, compared to its average volume of 4,234,465. The firm has a market cap of $53.64 billion, a price-to-earnings ratio of 13.63, a price-to-earnings-growth ratio of 1.20 and a beta of 1.01. The company has a quick ratio of 0.59, a current ratio of 0.71 and a debt-to-equity ratio of 0.69. Express Scripts has a 52 week low of $59.17 and a 52 week high of $98.98.
Express Scripts (NASDAQ:ESRX) last released its quarterly earnings data on Wednesday, October 31st. The company reported $2.43 earnings per share for the quarter, topping analysts’ consensus estimates of $2.42 by $0.01. The firm had revenue of $25.56 billion during the quarter, compared to analyst estimates of $25.11 billion. Express Scripts had a return on equity of 25.49% and a net margin of 4.65%. The business’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.51 earnings per share. Research analysts expect that Express Scripts will post 9.07 EPS for the current fiscal year.
In related news, insider Christine Houston sold 12,898 shares of the stock in a transaction that occurred on Friday, August 10th. The stock was sold at an average price of $85.00, for a total transaction of $1,096,330.00. Following the completion of the transaction, the insider now directly owns 110,908 shares of the company’s stock, valued at $9,427,180. The sale was disclosed in a filing with the SEC, which is available through this link. 0.79% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in ESRX. Principal Financial Group Inc. boosted its stake in Express Scripts by 17.4% during the first quarter. Principal Financial Group Inc. now owns 969,252 shares of the company’s stock valued at $66,956,000 after buying an additional 143,479 shares during the last quarter. CenturyLink Investment Management Co bought a new stake in shares of Express Scripts in the 2nd quarter valued at approximately $1,741,000. Indiana Trust & Investment Management CO bought a new stake in shares of Express Scripts in the 2nd quarter valued at approximately $1,879,000. DnB Asset Management AS bought a new stake in shares of Express Scripts in the 2nd quarter valued at approximately $16,974,000. Finally, Burke & Herbert Bank & Trust Co. bought a new stake in shares of Express Scripts in the 2nd quarter valued at approximately $285,000. 84.74% of the stock is owned by institutional investors.
Express Scripts Company Profile
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Further Reading: NASDAQ
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.